Constantin Mihai Lucaciu
Overview
Explore the profile of Constantin Mihai Lucaciu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buhas B, Muntean L, Ploussard G, Feciche B, Andras I, Toma V, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337322
Renal cell carcinoma (RCC) is the sixth most common cancer in men and is often asymptomatic, leading to incidental detection in advanced disease stages that are associated with aggressive histology...
2.
Buhas B, Toma V, Beauval J, Andras I, Couti R, Muntean L, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612705
The advent of Surface-Enhanced Raman Scattering (SERS) has enabled the exploration and detection of small molecules, particularly in biological fluids such as serum, blood plasma, urine, saliva, and tears. SERS...
3.
Lucaciu C
Pharmaceutics
. 2024 Feb;
16(2).
PMID: 38399317
In recent years, nanomedicine has experienced remarkable advancements, due to the development of new nanomaterials with outstanding properties that have demonstrated significant advantages over traditional medicines [...].
4.
Buhas B, Toma V, Crisan N, Ploussard G, Maghiar T, Stiufiuc R, et al.
Biosensors (Basel)
. 2023 Aug;
13(8).
PMID: 37622899
Renal cell carcinoma (RCC) represents the sixth most frequently diagnosed cancer in men and is asymptomatic, being detected mostly incidentally. The apparition of symptoms correlates with advanced disease, aggressive histology,...
5.
Nitica S, Fizesan I, Dudric R, Loghin F, Lucaciu C, Iacovita C
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36432692
The combination of magnetic hyperthermia with chemotherapy is considered a promising strategy in cancer therapy due to the synergy between the high temperatures and the chemotherapeutic effects, which can be...
6.
Lucaciu C, Nitica S, Fizesan I, Filip L, Bilteanu L, Iacovita C
Nanomaterials (Basel)
. 2022 Oct;
12(20).
PMID: 36296768
The collective organization of magnetic nanoparticles (MNPs) influences significantly their hyperthermic properties, relevant for their in vitro and in vivo applications. We report a systematic investigation of the effects of...
7.
Nitica S, Fizesan I, Dudric R, Barbu-Tudoran L, Pop A, Loghin F, et al.
Biomedicines
. 2022 Jul;
10(7).
PMID: 35884954
The applications of ferrimagnetic nanoparticles (F-MNPs) in magnetic hyperthermia (MH) are restricted by their stabilization in microscale aggregates due to magnetostatic interactions significantly reducing their heating performances. Coating the F-MNPs...
8.
Fizesan I, Iacovita C, Pop A, Kiss B, Dudric R, Stiufiuc R, et al.
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959431
The clinical translation of magnetic hyperthermia (MH) needs magnetic nanoparticles (MNPs) with enhanced heating properties and good biocompatibility. Many studies were devoted lately to the increase in the heating power...
9.
Iacovita C, Fizesan I, Nitica S, Florea A, Barbu-Tudoran L, Dudric R, et al.
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959308
Increasing the biocompatibility, cellular uptake, and magnetic heating performance of ferromagnetic iron-oxide magnetic nanoparticles (F-MNPs) is clearly required to efficiently induce apoptosis of cancer cells by magnetic hyperthermia (MH). Thus,...
10.
Stiufiuc G, Toma V, Onaciu A, Chis V, Lucaciu C, Stiufiuc R
Pharmaceutics
. 2021 Oct;
13(10).
PMID: 34683887
Chiral separation is an important issue for the pharmaceutical industry. Over the years, several separation methods have been developed, mainly based on chromatography. Their working principle is based on the...